Dr. Sheldon received his medical degree from the University of Michigan Medical School in 1975. He completed his general surgical residency with Kaiser Permanente Medical Center in Oakland, California and his cardiovascular fellowships at the University of California, Davis and the Montefiore Hospital and Medical Center in New York. In 1983, he entered private practice as a staff surgeon in several medical centers in Northern California performing cardiac, thoracic and vascular surgery. In 2003, he chose to become engaged in a highly productive career in the medical device industry, leading device development projects and providing expert consultative services to numerous device development firms. From 2003-2009, Murray was the Medical Director for Arbor Surgical Technologies, which developed a unique two-piece, sutureless aortic valve for clinical aortic valve replacement that was sold to Medtronic. Most recently, prior to joining FDA, he was the Medical Director for the minimally invasive surgical program at BioVentrix, Inc. and developed a catheter-based procedure for surgical ventricular reconstruction for heart failure patients. This device has recently obtained a CE mark in Europe. He also was the Medical Director for Solinas Medical, Inc. and was instrumental in developing a unique device for dialysis access. That device has recently received two 510(k) clearances. Dr. Sheldon has recently joined the FDA as the Associate Director for Technology and Innovation. He oversees the Center’s initiative to proactively facilitate medical device innovation to address unmet public health needs and to align what is traditionally done at FDA with what is required to support the U.S. medical device ecosystem. His primary focus is working with staff, the medical device industry, the clinical community, and others on ways to facilitate bringing innovative medical devices to the patients in the U.S. first in the world. Dr. Sheldon currently leads the Medical Device Reimbursement Task Force, identifying methods to streamline the path from FDA approval to reimbursement.